The Effects of the Attributable Fraction and the Duration of Symptoms on Burden Estimates of Influenza-associated Respiratory Illnesses in a High HIV Prevalence Setting, South Africa, 2013-2015
Overview
Authors
Affiliations
Background: The attributable fraction of influenza virus detection to illness (INF-AF) and the duration of symptoms as a surveillance inclusion criterion could potentially have substantial effects on influenza disease burden estimates.
Methods: We estimated rates of influenza-associated influenza-like illness (ILI) and severe acute (SARI-10) or chronic (SCRI-10) respiratory illness (using a symptom duration cutoff of ≤10 days) among HIV-infected and HIV-uninfected patients attending 3 hospitals and 2 affiliated clinics in South Africa during 2013-2015. We calculated the unadjusted and INF-AF-adjusted rates and relative risk (RR) due to HIV infection. Rates were expressed per 100 000 population.
Results: The estimated mean annual unadjusted rates of influenza-associated illness were 1467.7, 50.3, and 27.4 among patients with ILI, SARI-10, and SCRI-10, respectively. After adjusting for the INF-AF, the percent reduction in the estimated rates was 8.9% (rate: 1336.9), 11.0% (rate: 44.8), and 16.3% (rate: 22.9) among patients with ILI, SARI-10, and SCRI-10, respectively. HIV-infected compared to HIV-uninfected individuals experienced a 2.3 (95% CI: 2.2-2.4)-, 9.7 (95% CI: 8.0-11.8)-, and 10.0 (95% CI: 7.9-12.7)-fold increased risk of influenza-associated illness among patients with ILI, SARI-10, and SCRI-10, respectively. Overall 34% of the estimated influenza-associated hospitalizations had symptom duration of >10 days; 8% and 44% among individuals aged <5 and ≥5 years, respectively.
Conclusion: The marginal differences between unadjusted and INF-AF-adjusted rates are unlikely to affect policies on prioritization of interventions. HIV-infected individuals experienced an increased risk of influenza-associated illness and may benefit more from annual influenza immunization. The use of a symptom duration cutoff of ≤10 days may underestimate influenza-associated disease burden, especially in older individuals.
Kittikraisak W, Tinoco Y, Levine M, Mott J, Kanjanapattanakul W, Munayco C Int J Infect Dis. 2024; 149():107264.
PMID: 39426491 PMC: 11710853. DOI: 10.1016/j.ijid.2024.107264.
Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus.
Tortellini E, Fosso Ngangue Y, Dominelli F, Guardiani M, Falvino C, Mengoni F Viruses. 2023; 15(9).
PMID: 37766251 PMC: 10534440. DOI: 10.3390/v15091844.
Moyes J, Tempia S, Walaza S, McMorrow M, Cohen A, Treurnicht F Int J Infect Dis. 2023; 134:71-77.
PMID: 37211271 PMC: 10675839. DOI: 10.1016/j.ijid.2023.05.009.
The burden of RSV-associated illness in children aged < 5 years, South Africa, 2011 to 2016.
Moyes J, Tempia S, Walaza S, McMorrow M, Treurnicht F, Wolter N BMC Med. 2023; 21(1):139.
PMID: 37038125 PMC: 10088270. DOI: 10.1186/s12916-023-02853-3.
Tempia S, Moyes J, Cohen A, Walaza S, McMorrow M, Treurnicht F Influenza Other Respir Viruses. 2022; 16(3):438-451.
PMID: 35150059 PMC: 8983907. DOI: 10.1111/irv.12949.